User:MaynardClark/Joseph T. Coyle

Joseph T. Coyle, MD, Eben S. Draper Chair of Psychiatry & Neuroscience, Harvard Medical School, McLean Hospital.

http://www.mcleanhospital.org/biography/joseph-coyle Joseph T. Coyle, MD McLean Hospital Chief Scientific Officer Harvard Medical School Eben S. Draper Professor of Psychiatry and Neuroscience joseph_coyle@hms.harvard.edu Phone: 617.855.2101 Office Address:

Belmont campus - Mailman Research Center, Room 122

Education

 * 1969 MD, Johns Hopkins School of Medicine
 * Residency: 1973-1976 Psychiatry, Johns Hopkins Hospital
 * Fellowship: 1970-1973 NIMH, Laboratory of Julius Axelrod, PhD

Board Certifications

 * Psychiatry

Biography
Joseph T. Coyle, MD is the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard Medical School and was Chairman of the Consolidated Department of Psychiatry at Harvard (1991-2001). A Holy Cross College graduate, he received his MD from Johns Hopkins. He completed an internship in Pediatrics, a residency in Psychiatry and a fellowship with the Nobel laureate Julius Axelrod, PhD. He joined the Hopkins faculty in 1975 and was named the Distinguished Service Professor of Child Psychiatry in 1985.

Dr. Coyle is a member of the Institute of Medicine (1990), a fellow of the American Academy of Arts and Sciences (1993), and a Distinguished Fellow of the American Psychiatric Association. He is Past-President of the American College of Neuropsychopharmacology (2001) and of the Society for Neuroscience (1991). He is the editor of JAMA Psychiatry.

Joseph T. Coyle, M.D. holds the Eben S. Draper Chair of Psychiatry and Neuroscience at Harvard Medical School. From 1991 to 2001, he served as Chairman of the Consolidated Department of Psychiatry at Harvard Medical School, which included the nine hospital programs of psychiatry affiliated with the Medical School. After graduating from Holy Cross College, he received his medical degree (M.D.) from Johns Hopkins School of Medicine in 1969. Following an internship in Pediatrics, he spent three years at the National Institutes of Health as a research fellow in the laboratory of Nobel laureate Julius Axelrod, Ph.D. He returned to Hopkins in 1973 to complete his Psychiatric residency, in which he is board certified, and joined the faculty in 1975. In 1980, he was promoted to Professor of Neuroscience, Pharmacology and Psychiatry; and in 1982 he assumed the Directorship of the Division of Child and Adolescent Psychiatry, being named the Distinguished Service Professor in 1985.

Dr. Coyle's research interests include developmental neurobiology, mechanisms of neuronal vulnerability and psychopharmacology. In particular, he has carried out research on the role of glutamatergic neurons in the pathophysiology of neuropsychiatric disorders for 30 years. He has a long commitment to training. In the mid-1980s, he was the PI of a NIMH Training Grant that had a core curriculum, which introduced PhD fellows to psychiatric illnesses with patient demonstrations. While President of the Society of Neuroscience, he worked with NIMH to develop a minority Training Grant. For the last 10 years, he has served as co-PI on this grant, which was the foundation for minority mentoring and net-working for the Society. He has published over 500 scientific articles and has edited seven books. His research has been cited over 35,000 times, and his H-factor is 93. He has received continuous NIH funding for his research for 30 years and is the Director of an NIMH Conte Center on the Neurobiology of Schizophrenia (2001-11).

Dr. Coyle is a member of the Institute of Medicine of the National Academy of Sciences (1990), a fellow of the American Academy of Arts and Sciences (1993), a Distinguished Fellow of the American Psychiatric Association, a fellow of the American College of Psychiatry and fellow of the American Association for the Advancement of Science. He served on the National Advisory Mental Health Council for the National Institute of Mental Health (1990-94). He is Past-President of the American College of Neuropsychopharmacology (2001) and Past-President (1991) of the Society for Neuroscience, an organization with more than 35,000 members. He sits on over 20 journal editorial boards including JAMA and is the Editor-in-Chief of the Archives of General Psychiatry, the most highly cited journal in the field (citation impact:15.98).

Publications

 * Coyle JT, ed. Animal models of dementia: a synaptic neurochemical perspective. New York: Alan R. Liss, Inc., 1987.
 * Enna SJ, Coyle JT, eds. Pharmacological management of neurological and psychiatric disorders. New York: McGraw-Hill, 1998.
 * Hollander E, Kolevzon A, Coyle JT, eds. Textbook of autism spectrum disorders. Washington, DC: American Psychiatric Publishing, Inc., 2011.
 * Barrett E, Coyle JT, Williams M, eds. Translational neuroscience: applications in psychiatry, neurology and neurodevelopmental disorders. New York: Cambridge University Press, 2012.

PubMed search for Dr. Coyle

--

View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed Steingard RJ, Schmidt C, Coyle JT. Basic neuroscience: critical issues for understanding psychiatric disorders. Adolesc Med. 1998 Jun; 9(2):205-15, v. View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed View in: PubMed
 * Coyle JT. Farewell. JAMA Psychiatry. 2014 Dec 1; 71(12):1321-2.
 * Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry. 2014 Dec 1; 71(12):1323-31.
 * Balu DT, Coyle JT. Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochem Int. 2014 Sep; 75:76-8.
 * Balu DT, Takagi S, Puhl MD, Benneyworth MA, Coyle JT. D-Serine and Serine Racemase are Localized to Neurons in the Adult Mouse and Human Forebrain. Cell Mol Neurobiol. 2014 Apr; 34(3):419-35.
 * Santini MA, Balu DT, Puhl MD, Hill-Smith TE, Berg AR, Lucki I, Mikkelsen JD, Coyle JT. D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT2A receptor agonist DOI. Behav Brain Res. 2014 Feb 1; 259:242-6.
 * Coyle JT, Ongur D. Relapse in alcohol use disorder-reply. JAMA Psychiatry. 2013 Nov 1; 70(11):1248.
 * O'Connor JE, Coyle J, Bogue C, Spence LD, Last J. Age prediction formulae from radiographic assessment of skeletal maturation at the knee in an Irish population. Forensic Sci Int. 2014 Jan; 234:188.e1-8.
 * Coyle JT. Brain structural alterations induced by fetal exposure to cocaine persist into adolescence and affect behavior. JAMA Psychiatry. 2013 Oct; 70(10):1113-4.
 * Coyle JT. Nitric oxide and symptom reduction in schizophrenia. JAMA Psychiatry. 2013 Jul; 70(7):664-5.
 * Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S, Bolshakov VY, Coyle JT. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A. 2013 Jun 25; 110(26):E2400-9.
 * Konopaske GT, Bolo NR, Basu AC, Renshaw PF, Coyle JT. Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. Psychopharmacology (Berl). 2013 Nov; 230(1):57-67.
 * Coyle JT. Much more than a name change. JAMA Psychiatry. 2013 Jan; 70(1):8.
 * Li Y, Sacchi S, Pollegioni L, Basu AC, Coyle JT, Bolshakov VY. Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. Nat Commun. 2013; 4:1760.
 * Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, Graham B, Hiscock SD, Murray CW, Pathuri P, Rich SJ, Richardson CJ, Williams PA, Jhoti H. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol. 2012 Nov; 8(11):920-5.
 * Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012 Sep; 38(5):920-6.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA network journals: new names for the archives journals. Arch Intern Med. 2012 Jul 23; 172(14):1056.
 * Benneyworth MA, Coyle JT. Altered acquisition and extinction of amphetamine-paired context conditioning in genetic mouse models of altered NMDA receptor function. Neuropsychopharmacology. 2012 Oct; 37(11):2496-504.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network journals: new names for the archives journals. Arch Facial Plast Surg. 2012 Jul-Aug; 14(4):236.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: new names for the archives journals. Arch Pediatr Adolesc Med. 2012 Jul 1; 166(7):662.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Neurol. 2012 Jul 1; 69(7):817.
 * Coyle JT. Changing to JAMA Psychiatry. Arch Gen Psychiatry. 2012 Jul 1; 69(7):661.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Neurol. 2012 Jul; 69(7):817.
 * Coyle JT. Changing to JAMA Psychiatry. Arch Gen Psychiatry. 2012 Jul 1; 69(7):661.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Otolaryngol Head Neck Surg. 2012 Jul 1; 138(7):620.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Ophthalmol. 2012 Jul; 130(7):914.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: New Names for the Archives Journals. Arch Gen Psychiatry. 2012 Jul 1; 69(7):660.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network journals: new names for the archives journals. Arch Surg. 2012 Jul; 147(7):587.
 * Bauchner H, Albert DM, Coyle JT, Freischlag JA, Larrabee WF, Levine PA, Redberg RF, Redberg RA, Rivara FP, Robinson JK, Rosenberg RN. The JAMA Network Journals: new names for the archives journals. Arch Dermatol. 2012 Jul; 148(7):788.
 * Schaevitz LR, Picker JD, Rana J, Kolodny NH, Shane B, Berger-Sweeney JE, Coyle JT. Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders. Dev Neurobiol. 2012 Jun; 72(6):891-905.
 * Coyle JT. Changes in JAMA and the Archives of General Psychiatry: what they mean for readers and authors. Arch Gen Psychiatry. 2012 May; 69(5):447-8.
 * Balu DT, Coyle JT. Neuronal D-serine regulates dendritic architecture in the somatosensory cortex. Neurosci Lett. 2012 May 31; 517(2):77-81.
 * Benneyworth MA, Li Y, Basu AC, Bolshakov VY, Coyle JT. Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons. Cell Mol Neurobiol. 2012 May; 32(4):613-24.
 * Chen Y, Norton DJ, McBain R, Gold J, Frazier JA, Coyle JT. Enhanced local processing of dynamic visual information in autism: evidence from speed discrimination. Neuropsychologia. 2012 Apr; 50(5):733-9.
 * Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol. 2012; (213):267-95.
 * Bergeron R, Coyle JT. NAAG, NMDA receptor and psychosis. Curr Med Chem. 2012; 19(9):1360-4.
 * Sullivan SJ, Esguerra M, Wickham RJ, Romero GE, Coyle JT, Miller RF. Serine racemase deletion abolishes light-evoked NMDA receptor currents in retinal ganglion cells. J Physiol. 2011 Dec 15; 589(Pt 24):5997-6006.
 * Balu DT, Basu AC, Corradi JP, Cacace AM, Coyle JT. The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol Dis. 2012 Feb; 45(2):671-82.
 * Balu DT, Coyle JT. Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. Brain Res. 2011 May 25; 1392:1-7.
 * Coyle JT. Online first. Arch Gen Psychiatry. 2011 Apr 4; 68(4):339.
 * Benneyworth MA, Roseman AS, Basu AC, Coyle JT. Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Neurosci Lett. 2011 Jan 25; 488(3):267-71.
 * DeVito LM, Balu DT, Kanter BR, Lykken C, Basu AC, Coyle JT, Eichenbaum H. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav. 2011 Mar; 10(2):210-22.
 * Balu DT, Coyle JT. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev. 2011 Jan; 35(3):848-70.
 * Benneyworth MA, Basu AC, Coyle JT. Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology (Berl). 2011 Jan; 213(1):143-53.
 * Mustafa AK, Ahmad AS, Zeynalov E, Gazi SK, Sikka G, Ehmsen JT, Barrow RK, Coyle JT, Snyder SH, Doré S. Serine racemase deletion protects against cerebral ischemia and excitotoxicity. J Neurosci. 2010 Jan 27; 30(4):1413-6.
 * Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010; 12(3):359-82.
 * Reed BT, Sullivan SJ, Tsai G, Coyle JT, Esguerra M, Miller RF. The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina. Eur J Neurosci. 2009 Dec; 30(12):2308-17.
 * Han L, Picker JD, Schaevitz LR, Tsai G, Feng J, Jiang Z, Chu HC, Basu AC, Berger-Sweeney J, Coyle JT. Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse. 2009 Aug; 63(8):625-35.
 * Ghose S, Chin R, Gallegos A, Roberts R, Coyle J, Tamminga C. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophr Res. 2009 Jun; 111(1-3):131-7.
 * Coyle JT. MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. Proc Natl Acad Sci U S A. 2009 Mar 3; 106(9):2975-6.
 * Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L, Jiang ZI, Benneyworth MA, Froimowitz MP, Lange N, Snyder SH, Bergeron R, Coyle JT. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry. 2009 Jul; 14(7):719-27.
 * Coyle JT. Erratum: "Prevalence, heritability, and prospective risk factors for anorexia nervosa" (2006;63[3]:305-312). Arch Gen Psychiatry. 2008 Sep; 65(9):994.
 * Regenberg A, Mathews DJ, Blass DM, Bok H, Coyle JT, Duggan P, Faden R, Finkel J, Gearhart JD, Hillis A, Hoke A, Johnson R, Johnston M, Kahn J, Kerr D, King P, Kurtzberg J, Liao SM, McDonald JW, McKhann G, Nelson KB, Rao M, Siegel AW, Smith K, Solter D, Song H, Sugarman J, Vescovi A, Young W, Greely HT, Traystman RJ. The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb Blood Flow Metab. 2009 Jan; 29(1):1-9.
 * Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008 May; 31(5):234-42.
 * Eaton DL, Daroff RB, Autrup H, Bridges J, Buffler P, Costa LG, Coyle J, McKhann G, Mobley WC, Nadel L, Neubert D, Schulte-Hermann R, Spencer PS. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit Rev Toxicol. 2008; 38 Suppl 2:1-125.
 * Lawson-Yuen A, Liu D, Han L, Jiang ZI, Tsai GE, Basu AC, Picker J, Feng J, Coyle JT. Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice. Brain Res. 2007 Nov 14; 1180:1-6.
 * Han L, Wong DL, Tsai G, Jiang Z, Coyle JT. Promoter analysis of human glutamate carboxypeptidase II. Brain Res. 2007 Sep 19; 1170:1-12.
 * Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis. 2007 Jul; 11(4):491-507.
 * Coyle JT. What can a clock mutation in mice tell us about bipolar disorder? Proc Natl Acad Sci U S A. 2007 Apr 10; 104(15):6097-8.
 * Bergeron R, Imamura Y, Frangioni JV, Greene RW, Coyle JT. Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J Neurochem. 2007 Jan; 100(2):346-57.
 * Coyle JT. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006 Dec; 10(3-4):221-33.
 * Siekmeier PJ, Hasselmo ME, Howard MW, Coyle J. Modeling of context-dependent retrieval in hippocampal region CA1: implications for cognitive function in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):177-90.
 * Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron. 2006 Oct 5; 52(1):139-53.
 * Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 Jul-Aug; 26(4-6):365-84.
 * Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry. 2007 Jan 15; 61(2):162-6.
 * Coyle JT. A brief overview of N-acetylaspartate and N-acetylaspartylglutamate. Adv Exp Med Biol. 2006; 576:1-6; discussion 361-3.
 * Coyle JT. Glial metabolites of tryptophan and excitotoxicity: coming unglued. Exp Neurol. 2006 Jan; 197(1):4-7.
 * Picker JD, Coyle JT. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? Harv Rev Psychiatry. 2005 Jul-Aug; 13(4):197-205.
 * Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, Cohen B, Goff DC. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005 Jan 30; 138(1):23-31.
 * Martina M, B-Turcotte ME, Halman S, Tsai G, Tiberi M, Coyle JT, Bergeron R. Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. J Physiol. 2005 Mar 15; 563(Pt 3):777-93.
 * Bergeron R, Coyle JT, Tsai G, Greene RW. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology. 2005 Jan; 30(1):7-16.
 * Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol. 2004 Oct 15; 68(8):1507-14.
 * Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004 Sep; 161(9):1705-8.
 * Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JT. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A. 2004 Jun 1; 101(22):8485-90.
 * Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol. 2004; 59:491-515.
 * Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, Kleinman JE. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology. 2004 Jan; 29(1):117-25.
 * Javitt DC, Coyle JT. Decoding schizophrenia. Sci Am. 2004 Jan; 290(1):48-55.
 * Tsai G, Dunham KS, Drager U, Grier A, Anderson C, Collura J, Coyle JT. Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse. 2003 Dec 15; 50(4):285-92.
 * Coyle JT, Pine DS, Charney DS, Lewis L, Nemeroff CB, Carlson GA, Joshi PT, Reiss D, Todd RD, Hellander M. Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2003 Dec; 42(12):1494-503.
 * Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):32-8.
 * Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003 Nov; 1003:318-27.
 * Coyle JT. Use it or lose it--do effortful mental activities protect against dementia? N Engl J Med. 2003 Jun 19; 348(25):2489-90.
 * Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron. 2003 Apr 24; 38(2):157-60.
 * Flores C, Coyle JT. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology. 2003 Jul; 28(7):1227-34.
 * Coyle JT. A continuing commitment to excellence. Arch Gen Psychiatry. 2002 Nov; 59(11):977.
 * Coyle JT, Manji HK. Getting balance: drugs for bipolar disorder share target. Nat Med. 2002 Jun; 8(6):557-8.
 * Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002 Apr; 1(2):183-9.
 * Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002; 42:165-79.
 * Frazier JA, Doyle R, Chiu S, Coyle JT. Treating a child with Asperger's disorder and comorbid bipolar disorder. Am J Psychiatry. 2002 Jan; 159(1):13-21.
 * Leski ML, Hassinger LC, Valentine SL, Baer JD, Coyle JT. L-type calcium channels reduce ROS generation in cerebellar granule cells following kainate exposure. Synapse. 2002 Jan; 43(1):30-41.
 * Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001 Sep; 158(9):1367-77.
 * Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1; 49(3):289-99.
 * Leski ML, Valentine SL, Baer JD, Coyle JT. Insulin-like growth factor I prevents the development of sensitivity to kainate neurotoxicity in cerebellar granule cells. J Neurochem. 2000 Oct; 75(4):1548-56.
 * Leveque JC, Macías W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li XM, Coyle JT, Huganir RL, Heckers S, Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci. 2000 Jun 1; 20(11):4011-20.
 * Nguyen TV, Brownell AL, Iris Chen YC, Livni E, Coyle JT, Rosen BR, Cavagna F, Jenkins BG. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse. 2000 Apr; 36(1):57-65.
 * Price BH, Adams RD, Coyle JT. Neurology and psychiatry: closing the great divide. Neurology. 2000 Jan 11; 54(1):8-14.
 * Coyle JT, Schwarcz R. Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 2000 Jan; 57(1):90-3.
 * Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C, Coyle JT. Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol. 1999 Dec 6; 415(1):52-64.
 * Lindley CR, Coyle JT. Psychopharmacologist as family doctor: complications in the joint treatment of a husband and wife. Harv Rev Psychiatry. 1999 Nov-Dec; 7(4):222-9.
 * Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov; 156(11):1822-5.
 * Leski ML, Valentine SL, Coyle JT. L-type voltage-gated calcium channels modulate kainic acid neurotoxicity in cerebellar granule cells. Brain Res. 1999 May 15; 828(1-2):27-40.
 * Coyle JT. Ice-nine and human prion disease. Harv Rev Psychiatry. 1999 Mar-Apr; 6(6):331-3.
 * Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999 Mar; 156(3):467-9.
 * Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi AR, Coyle JT. Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol. 1999 Jan; 55(1):179-85.
 * Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999 Jan; 56(1):21-7.
 * Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15730-4.
 * Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1; 44(11):1081-9.
 * Tsai G, van Kammen DP, Chen S, Kelley ME, Grier A, Coyle JT. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry. 1998 Oct 15; 44(8):667-74.
 * Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998 Sep; 155(9):1207-13.
 * Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998 Aug; 286(2):1020-5.
 * Schwartz PJ, Coyle JT. Effects of overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. Synapse. 1998 Jul; 29(3):206-12.
 * Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res. 1998 Jun 8; 795(1-2):341-8.
 * Tsai GE, Ragan P, Chang R, Chen S, Linnoila VM, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry. 1998 Jun; 155(6):726-32.
 * View in: PubMed
 * Passani L, Elkabes S, Coyle JT. Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Res. 1998 May 25; 794(1):143-5.
 * Schwartz PJ, Reaume A, Scott R, Coyle JT. Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum. Brain Res. 1998 Apr 6; 789(1):32-9.
 * Luthi-Carter R, Berger UV, Barczak AK, Enna M, Coyle JT. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3215-20.
 * Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998; 49:173-84.
 * Orlando LR, Luthi-Carter R, Standaert DG, Coyle JT, Penney JB, Young AB. N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci Lett. 1997 Oct 31; 236(2):91-4.
 * Passani LA, Vonsattel JP, Coyle JT. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 1997 Oct 24; 772(1-2):9-22.
 * Coyle JT, Mallet J. Disease, transplantation and regeneration. Curr Opin Neurobiol. 1997 Oct; 7(5):663-5.
 * Passani LA, Vonsattel JP, Carter RE, Coyle JT. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol Chem Neuropathol. 1997 Jun; 31(2):97-118.
 * Coyle JT. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis. 1997; 4(3-4):231-8.
 * Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT. Kainic acid induces apoptosis in neurons. Neuroscience. 1996 Dec; 75(4):1047-55.
 * Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996 Dec; 153(12):1628-30.
 * Simonian NA, Getz RL, Leveque JC, Konradi C, Coyle JT. Kainate induces apoptosis in neurons. Neuroscience. 1996 Oct; 74(3):675-83.
 * Didier M, Bursztajn S, Adamec E, Passani L, Nixon RA, Coyle JT, Wei JY, Berman SA. DNA strand breaks induced by sustained glutamate excitotoxicity in primary neuronal cultures. J Neurosci. 1996 Apr 1; 16(7):2238-50.
 * Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A. 1996 Jan 23; 93(2):749-53.
 * Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 1996; 36:83-106.
 * Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996 Jan-Feb; 3(5):241-53.
 * Coyle JT. The neuroscience perspective and the changing role of the psychiatrist : the challenge for psychiatric educators. Acad Psychiatry. 1995 Dec; 19(4):202-12.
 * Coyle JT. Food for thought. Nat Med. 1995 Oct; 1(10):1006-7.
 * Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995 Oct; 52(10):829-36.
 * Baer L, Cukor P, Jenike MA, Leahy L, O'Laughlen J, Coyle JT. Pilot studies of telemedicine for patients with obsessive-compulsive disorder. Am J Psychiatry. 1995 Sep; 152(9):1383-5.
 * Schwartz PJ, Berger UV, Coyle JT. Mice transgenic for copper/zinc superoxide dismutase exhibit increased markers of biogenic amine function. J Neurochem. 1995 Aug; 65(2):660-9.
 * Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 1995 Aug; 46(5):531-40.
 * Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995 Aug; 152(8):1213-5.
 * Baer L, Jacobs DG, Cukor P, O'Laughlen J, Coyle JT, Magruder KM. Automated telephone screening survey for depression. JAMA. 1995 Jun 28; 273(24):1943-4.
 * Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995 Mar; 152(3):332-40.
 * Berger UV, Carter RE, McKee M, Coyle JT. N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann cells in the peripheral nervous system. J Neurocytol. 1995 Feb; 24(2):99-109.
 * Berger UV, Carter RE, Coyle JT. The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolysing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junction. Neuroscience. 1995 Feb; 64(4):847-50.
 * Tsai G, Cork LC, Slusher BS, Price D, Coyle JT. Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. Brain Res. 1993 Dec 3; 629(2):305-9.
 * Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993 Oct 29; 262(5134):689-95.
 * Puttfarcken PS, Getz RL, Coyle JT. Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U78517F in primary cultures of cerebellar granule cells. Brain Res. 1993 Oct 8; 624(1-2):223-32.
 * Tsai G, Slusher BS, Sim L, Coyle JT. Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. J Chem Neuroanat. 1993 Sep-Oct; 6(5):277-92.
 * Puttfarcken PS, Handen JS, Montgomery DT, Coyle JT, Werling LL. N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [3H]norepinephrine release from rat hippocampal slices. J Pharmacol Exp Ther. 1993 Aug; 266(2):796-803.
 * Puttfarcken PS, Lyons WE, Coyle JT. Dissociation of nitric oxide generation and kainate-mediated neuronal degeneration in primary cultures of rat cerebellar granule cells. Neuropharmacology. 1992 Jun; 31(6):565-75.
 * Coyle JT. Basic models of Alzheimer's disease. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A:35A.
 * Schwarcz R, Bennett JP, Coyle JT. Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease. J Neurochem. 1977 Apr; 28(4):867-9.

Awards and honors

 * 1968 - Henry Strong Denison Research Scholarship
 * 1969 - Alpha Omega Alpha Student Research Award
 * 1978 - A.E.Bennett Award in Basic Science
 * 1979 - John Jacob Abel Award
 * 1979 - Sato International Memorial Award
 * 1982 - Daniel Efron Award
 * 1985 - Foundations' Fund Prize for Research in Psychiatry
 * 1986 - Alpha Omega Alpha Honor Society
 * 1990 - Institute of Medicine of the National Academy of Sciences
 * 1990 - Nancy and Daniel Weisman Award for Research on Mental Retardation
 * 1991 - Edward A. Strecker Award
 * 1991 - Gold Medal Award
 * 1991 - 1992 - President
 * 1992 - William R. McAlpin, Jr. Research Achievement Award
 * 1994 - Fellow
 * 1997 - Award for Neuropsychiatric Research
 * 1997 - Exemplary Psychiatrist Award
 * 2001 - 2002 - President
 * 2001 - 2001 - Highly Cited Researchers Award
 * 2001 - 2004 - Council
 * 2001 - Special Achievement Award
 * 2004 - Lieber Prize for Schizophrenia Research
 * 2006 - Fellow
 * 2007 - 2007 Sanctae Crucis Award
 * 2007 - 2008 Julius Axelrod Award

External references

 * Harvard Catalyst profile for Joseph T. Coyle, MD
 * McLean Hospital profile for Joseph T. Coyle, MD